Levy and colleagues [15] addressed the question of cancer risk reduction with GLP-1 receptor agonist use in adult patients with obesity in a large-scale cohort study using the TriNetX US Collaborative Network database (2013–2023). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.